The experience of accommodating privacy restrictions during implementation of a large-scale surveillance study of an osteoporosis medication
| Autor: | Midkiff, Kirk D, Andrews, Elizabeth B, Gilsenan, Alicia W, Deapen, Dennis M, Harris, David H, Schymura, Maria J, Hornicek, Francis J |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Time Factors pharmacoepidemiology privacy Interviews as Topic postmarketing product surveillance Neoplasms Teriparatide Humans survey Registries Pharmacology & Pharmacy Aged Bone Density Conservation Agents public health Pharmacology and Pharmaceutical Sciences Middle Aged United States Product Surveillance Postmarketing retrospective studies oncology Public Health and Health Services Osteoporosis Female epidemiology |
| Zdroj: | Pharmacoepidemiology and drug safety, vol 25, iss 8 |
| Popis: | PurposeTo explore whether privacy restrictions developed to protect patients have complicated research within a 15-year surveillance study conducted with US cancer registries.MethodsData from enrolling 27 cancer registries over a 10-year period were examined to describe the amount of time needed to obtain study approval. We also analyzed the proportion of patients that completed a research interview out of the total reported by the registries and examined factors thought to influence this measure.ResultsThe average length of the research review process from submission to approval of the research was 7 months (range |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|